Cargando…
Oral Delivery of Novel Recombinant Lactobacillus Elicit High Protection against Staphylococcus aureus Pulmonary and Skin Infections
Staphylococcus aureus is a leading cause of nosocomial and community-associated infection worldwide; however, there is no licensed vaccine available. S. aureus initiates infection via the mucosa; therefore, a mucosal vaccine is likely to be a promising approach against S. aureus infection. Lactobaci...
Autores principales: | Pan, Na, Liu, Bohui, Bao, Xuemei, Zhang, Haochi, Sheng, Shouxin, Liang, Yanchen, Pan, Haiting, Wang, Xiao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473125/ https://www.ncbi.nlm.nih.gov/pubmed/34579221 http://dx.doi.org/10.3390/vaccines9090984 |
Ejemplares similares
-
Oral Vaccination with Engineered Probiotic Limosilactobacillus reuteri Has Protective Effects against Localized and Systemic Staphylococcus aureus Infection
por: Pan, Na, et al.
Publicado: (2023) -
Oral Administration with Recombinant Attenuated Regulated Delayed Lysis Salmonella Vaccines Protecting against Staphylococcus aureus Kidney Abscess Formation
por: Liang, Yanchen, et al.
Publicado: (2022) -
Vaccine Composition Formulated with a Novel Lactobacillus-Derived Exopolysaccharides Adjuvant Provided High Protection against Staphylococcus aureus
por: Zhang, Haochi, et al.
Publicado: (2021) -
Mammary γδ T cells promote IL-17A-mediated immunity against Staphylococcus aureus-induced mastitis in a microbiota-dependent manner
por: Pan, Na, et al.
Publicado: (2023) -
Novel exopolysaccharide derived from probiotic Lactobacillus pantheris TCP102 strain with immune-enhancing and anticancer activities
por: Sheng, Shouxin, et al.
Publicado: (2022)